Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지

Current Status of Genomic Epidemiology Reseach

유전체 역학연구의 동향

  • Lee, Kyoung-Mu (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Kang, Dae-Hee (Department of Preventive Medicine, Seoul National University College of Medicine)
  • 이경무 (서울대학교 의과대학 예방의학교실) ;
  • 강대희 (서울대학교 의과대학 예방의학교실)
  • Published : 2003.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Genomic epidemiology is defined as 'an evoking field of inquiring that uses the systematic application of epidemiologic methods are approaches in population-based studies of the impact of human genetic variation on health and disease (Khoury, 1998)'. Most human diseases are caused by the intricate interaction among environmental exposures and genetic susceptibility factors. Susceptibility genes involved in disease pathogenesis are categorized into two groups: high penetrance genes (i.e., BRAC1, RB, etc.) and lour penetranoe genes (i.e., GSTs, Cyps, XRCC1, ets.), and low penetrance susceptibility genes has the higher priority for epidemiological research due to high population attributable risk. In this paper, the summarized results of the association study between single nucleotide polymorphisms (SNPs) and breast cancer in Korea were introduced and the international trends of genomic epidemiology research were reviewed with an emphasis on internee-based case-control and cohort consortium.

Keywords

References

  1. Schulte PA, Perera FP. A conceptual and historical framework for molecular epidemiology. In: Schulte PA, Perera FP, editors. Molecular epidemiology: principles andpractices, SanDieago: Academic Press; 1993.p.3-44
  2. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology, New York, NY: Oxford University Press; 1993. p.3-25
  3. Khoury MJ, Dorman JS. The human genome epidemiology network (HuGE Net).AmJ Epidemiol 1998; 148:1-3 https://doi.org/10.1093/aje/148.1.1
  4. Carporaso N. Selection of candidate genes for population studies. In: Vineis P, Malats N, Lang M, d' Errico A, Caporaso N, Cuzick J, Boffeta P, editors. Metabolic polymorphisms and susceptibility to Cancer. Lyon: IARC Scientific Publishers; 1999.p. 23-36
  5. Zheng W. Epidemiological studies of genetic factors for cancer. In: Nasca PC, Pastides H, editors. Fundamentals of cancer epidemiology. Maryland: An Aspen Publications; 2001.p.103-121
  6. Sherry ST, Ward M, Sirotkin K. Use of molecular variation in the NCBI dbSNP database. HumMutat2000;15(1): 68-75 https://doi.org/10.1002/(SICI)1098-1004(200001)15:1<68::AID-HUMU14>3.0.CO;2-6
  7. Thorisson GA, Stein LD. The SNP consortium website: past, present and future. Nucleic AcidsRes 2003;31(1): 124-127 https://doi.org/10.1093/nar/gkg052
  8. Fredman D, Siegfried M, YuanYP, Bork P, Lehvaslaiho H, Brookes AI. HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources. Nucleic AcidsRes 2002;30(1): 387-391 https://doi.org/10.1093/nar/30.1.387
  9. Inoko H. PCR-RFLP method holds great promise for complete HLA class II genotyping. Tissue Antigens 1990; 36(2): 88-92 https://doi.org/10.1111/j.1399-0039.1990.tb01806.x
  10. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Hum Mutat 1993; 2(5): 338-346 https://doi.org/10.1002/humu.1380020503
  11. Howell WM,Jobs M, Gyllensten U, Brooks AI. Dynamic allele-specific hybridization. Nature Biotechnology 1999; 17:87-88 https://doi.org/10.1038/5270
  12. Tapp I, Malmberg L, Rennel E, Wik M, Syvanen AC. Homogeneous scoring of single-nucleotide polymorphisms: comparison of the 5' -nuclease TaqMan assay and Molecular Beacon probes. Biotechniques 2000;28(4): 732-728
  13. Hamajima N, SaitoT, MatsuoK, TajimaK. Competitive amplification and unspecific amplification in polymerase chain reaction with confronting two-pair primers. J Mol Diagn2002; 4: 103-107 https://doi.org/10.1016/S1525-1578(10)60688-5
  14. Nyren P, Karamohamed S, Ronaghi M. Detection of single-base changes using a bioluminometric primer extension assay. AnalBiochem 1997; 244(2): 367-373
  15. Ross P, Hall L, Smimov I, Haff L. High level multiplex genotyping by MALDITOF mass spectrometry. Nature Biotechnology1998; 16:1347-1351 https://doi.org/10.1038/4328
  16. Santacrone R, RattiA, CaroliF, Foglieni B, Ferraris A, Cremonesi L, Margaglione M; Seri M, Ravazzolo R, Restagno G, Dallapiccola B, Rappaport E, Pollack ES, Surrey S, Ferrari M, Fortina P. Analysis of clinically relevant single-nucleotide polymorphisrns by use of microelectronic array technology. Clinical Chemistry 2002; 48(12):2124-2130
  17. Yager JD Endogenous estrogens as carcinogens through metabolic activation. J NatlCancer InstMonagr 2000;27:67-73
  18. Madigan MP, Ziegler RG, Benichou J, Byme C, HooverRN. Proportion of breast cancercases in the UnitedStatesexplained by well-established risk factors. J Natl Cancer Inst 1995; 87(22): 1681-1685 https://doi.org/10.1093/jnci/87.22.1681
  19. Kang D. Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. J Biochem Mol BioI 2003; 36(1): 28-34 https://doi.org/10.5483/BMBRep.2003.36.1.028
  20. Park SK, Yoo KY, Lee SJ, Kim SU, Ahn SH, Noh DY, Choe KJ, Strickland PT, Hirvonen A, Kang DH. Alcohol consumption, glutathione S-transferase Ml and Tl genetic polymorphisms and breast cacner risk. Pharmacogenetics 2000; 10: 301-309 https://doi.org/10.1097/00008571-200006000-00004
  21. Yim DS, Park SK, Yoo KY, Yoon KS, Chung HR, Ahn SH, Noh DY, Choe KJ, Cho SH, Jang U, Shin SG, Strickland PT, Hirvonen A, KangD. Relationship between the Val 158 Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 2001;11:279-286 https://doi.org/10.1097/00008571-200106000-00001
  22. Watanabe J, Shimada T, Gillam EMJ, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Association of CYPIBI genetic polymorphism with incidence to breastand lung cancer. Pharmacogenetics 2000; 10: 25-33. https://doi.org/10.1097/00008571-200002000-00004
  23. Zheng W, Xie DW,Jin F, ChengJ R, Dai Q, Wen WQ, Shu XO, Gao YT. Genetic polymorphism of cytochorme P450-IBI andrisk of breastcancer. Cancer Epidemiol Biomarkers Prev 2000;9: 147-150
  24. Bailey LR, Roodi N, Dupont WD, ParI FF. Association of cytochrome P450 IB I (CYP IBI) polymorphism with steroid receptor status in breastcancer. Cancer Res 1998;58:5038-5041
  25. Ko Y, Abel J, Harth V, Brde P, Antony C, Donat S, Fischer HP, Oritiz-Pallardo ME, Thier R, Sachinidis A, VetterH, BoltHM, Herberhold C, Bruning T. Association of CYPIBl codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53in tumortissue. Cancer Res 2001;61:4398-4404
  26. Kim SU, Park SK, Yoo KY, Yoon KS, Choi JY, Noh DY, Ahn SH, Choe KJ, Strickland PT, Hirvonen A, Kang D: XRCCl genetic polymorphism and breast cancer risk, Pharmacogenetics 2002; 12: 335-338 https://doi.org/10.1097/00008571-200206000-00010
  27. Park SK, KangD, Noh DY,LeeKM,Kim SU, Choi JY, Choi 1M, Shin AS, Kim JR, Ahn SH, Choe KJ, Hirvonen A, Strickland PT, Yoo KY:Reproductive factors, glutathione S-transferase MI and Tl genetic polymorphism and breast cancer risk. BreastCancer Res Treat 2003; 78: 89-96 https://doi.org/10.1023/A:1022113713226
  28. Lee KM,Abel J, Ko Y, Harth V, Park WY, Seo JS,Y00 KY,Choi JY,Shin A, Ahn SH, Noh DY, Hirvonen A, Kang D: Genetic polymorphisms of CYP19 and CYPlBl, alcohol use, and breast cancer risk. Br J Cancer 2003;88:675-678 https://doi.org/10.1038/sj.bjc.6600761
  29. Choi JY,AbeI J, Neuhaus T, Ko Yon,Harth V, Hamajima N, Tajima K, Yoo KY, Park SK, Noh DY, Han W, Choe KJ, Ahn SH, Kim SU, Hirvonen A, Kang D: Role of alcohol and genetic polymorphisms of CYP2El and ALDH2 in breast cancer development. Pharmacogenetics 2003; 13(2): 67-72 https://doi.org/10.1097/00008571-200302000-00002
  30. Lee KM,Park SK, Kim SU, Doll MA,Yoo KY, Ahn SH, Noh DY, Hirvonen A, Hein DW, Kang D: N-acetyltransferase (NATl, NAT2) and glutathione S-transferase (GSTMl, GSITl) polymorphisrns in breast cancer. Cancer Lett 2003; 196(2): 179-186 https://doi.org/10.1016/S0304-3835(03)00311-2
  31. Choi JY, Hamajima N, Tajima K, Yoo KY, Yoon KS, Park SK, Kim Su, Lee KM,Noh DY, Ahn SH, Choe KJ, Han W, Hirvonen A, Kang D: OGGl Ser326Cys Polymorphism and breast cancer risk among Asian women. BreastCancer Resand Treat 2003; 79(1): 59-62 https://doi.org/10.1023/A:1023305826726
  32. Cuzick J. Interaction, subgroup analysis and sample size. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso, Cuzick J, Boffettan P, editors. Metabolic polymorphisms and susceptibility to Cancer, Lyon: IARC Scientific Publishers; 1999. p. 109-121
  33. Khoury MJ, Little J. Human genome epidemiologic reviews: The beginning of something HuGE. Am J Epidemiol 2000; 151(1): 2-3 https://doi.org/10.1093/oxfordjournals.aje.a010117
  34. Engel LS, Taioli E, Pfeiffer R, GarciaClosasM, MarcusPM, Lan Q, Boffetta P, VineisP, Autrup H, Bell DA, BranchRA, Brockmoller J,Daly AK, Heckbert SR, Kalina I, KangD, KatohT, Lafuente A, Lin HJ, Romkes M, Taylor JA, Rothman N. Pooled analysis and meta-analysis of Glutathione S-trarisferase Ml and bladder cancer: a HuGE review. Am J Epidemiol 2002; 156(2):95-109 https://doi.org/10.1093/aje/kwf018
  35. Taioli E. International collaborative study on genetic susceptibility to environmental carcinogens. CancerEpidemiol Biomarkers Prev 1999; 8:727-728
  36. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell' Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein OW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang O, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni n, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Pari FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg 0, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet 0, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. CancerEpidemiol Biomarkers Prev 2001; 10(12): 1239-1248处돀ᢰﾖ⨀⁊렼삫—⨀㄄돐—⨀ィ—⨀끟ὁ⸱〱㘯〱㤸ⴰㄴ㤨㠳⤹〰ㄳⴴᨀ볬蒱뷬ꂜ냪떬谀ᔀ鱡䦔셑쀾頗鬘領䝇侖邝垐浇€消䙁끟ὁ샸♁Ȁ܀ἀ؀Ā끟ὁ鱡䦔셑쀾끟ὁ頗鬘領䝇梵⨀ᨀĀ侖邝垐浇袵⨀ᔀȀ頗鬘領䝇ꢵ⨀ᨀ侖邝垐浇좵⨀ᔀ얖⨀⨀ȀĀ넂돐碧—⨀䠽傰ﾖ⨀぀⸷㐰ⴳ㈲㐀Ā鳪떭賫름룭馔駭验᠀뀿﷿￿￿䙇삵嚝뎲浇€镆䱁぀぀ȀȀḀЀĀ぀뀿぀﷿￿￿䙇—⨀ĀĀ삵嚝뎲浇᢫—⨀᠀Ȁ﷿￿￿䙇㢫—⨀Ā삵嚝뎲浇墫—⨀᠀袛얖⨀碪—⨀Ȁ﷿￿￿䙇뢪—⨀ĀĀ삵嚝뎲浇?—⨀᠀Ȁ⸀鳪떭賫름룭馔駭验⸀鳪떭賫름룭馔駭验⸀鳪떭賫름룭馔駭验㄀돐—⨀〽₧—⨀处돐ᢰﾖ⨀⁊렼?⨀㄄돐⨀袧—⨀
  37. Vineis P., Marinelli D., Autrup H., Brockmoller J., Cascorbi I., Daly AK., Golka H., Okkels K., Risch A., Rothman N., Sim E., Taioli E. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomakers Prev 2001; 10: 1249-1252
  38. Stucker I.,Boffetta P., Anttila S., Benhamou S" Hirvonen A., London S., and Taioli E. Lack of Interaction between Asbestos Exposure and Glutathione S-Transferase Ml and Tl genotype in lung carcinogenesis. Cancer EpidemiolBiomarkers Prev 2001; 10: 1253-1258
  39. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingeiman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002; 7(3): 230-241 https://doi.org/10.1080/13547500210121882
  40. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz O, Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-SundbergM, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg O, Seidegard J, Shields P, Strange RC, Stucker I, ToFigueras J, Brennan P, Taioli E. Meta- and pooled analyses of the effects of glutathione S-transferase Ml polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002; 23(8): 1343-1350.฀焂考犺Ȁ犺Ȁ̀￿￿岀剻ꐀ䃇萃藲贃ഀ￿ᯇ萃ఀ뀄?⨀耀?⨀ࠀᯇ萃ഀĀ퀶倀䠭㷄唿Ȁ퀅?⨀฀考憺Ȁ憺Ȁ̀￿￿ ?⨀퀅?⨀ https://doi.org/10.1093/carcin/23.8.1343
  41. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-SundbergM, Kihara M, Rannug A, Ryberg D, Stucker I, Sugimura H, Taioli E. Pooled analysis of the CYPIAI exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003; 14(4):339-346 https://doi.org/10.1023/A:1023956201228
  42. Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Garte S, Haugen A, Hirvonen A, Anttila S, Kalina I, Le Marchand L, London SJ, Rannug A, Romkes M, Salagovic J, Schoket B, Gaspari L, Taioli E. CYPIAI and GSTMI genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003; 24(5): 875-882 https://doi.org/10.1093/carcin/bgg026
  43. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Kalina I, Kremers P, Le Marchand L, London S, Rannug A, Romkes M, Schoket B, Seidegard J, Strange RC, Stucker I, To Figueras J, Garte S. Polymorphisms in CYPIAI, GSTMI, GS1TI and lung cancer below the age of 45 years. Int J Epidemiol 2003; 32(1): 60-63 https://doi.org/10.1093/ije/dyg001
  44. Vineis P, Veglia F, Benhamou S, Butkiewicz 0, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman Sundberg M, Kihara M, Kiyohara C, Kremers P, Le Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P, Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E. CYPJAI T3801C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 2003; 104(5): 650-657 https://doi.org/10.1002/ijc.10995
  45. Meeting Summary.NATIONAL CANCER INSTITUTE Consortium of Cohorts Minutes, Maryland, November 15-16, 2001 (http://ospahome.nci.nih.gov /cohort/ summaries/novO1 summary.html)
  46. Protocol for the UK biobank - a study of genes, environement and health - Feb. 14, 2002. (http://www.ukbiobank.ac.uk/ documents/ draftprotocol.pdf)
  47. Watanabe S, Tsugane S, Sobue T, Konishi M, Baba S. Study design and organization of the JPHC study. Japan Public Health Center-based prospective study on cancer and cardiovascular diseases. J Epidemiol 2001; 11(6 Suppl): S3-7 https://doi.org/10.2188/jea.11.6sup_3
  48. Ohno Y, Tamakoshi A; JACC Study Group. Japan collaborative cohort study for evaluation of cancer risk sponsored by monbusho (JACC study). J Epidemiol 2001; 11(4): 144-150 https://doi.org/10.2188/jea.11.144
  49. Tajima K. Protocol of large-scaled multicenter genome cohort in Japan. Korea-Japan Joint Meeting on cohort study for cancer research. Korea National Cancer Center. Seoul, Korea. March 24, 2003 50. Yoo KY, Shin HR, Chang SH, Lee KS, Park SK, Kang D, Lee DH. Koean multicenter cancer cohort study including a biological material bank (KMCC-l). Asian PacJ CancerPrev 2002; 3(1): 85-92